Jiang Liu

Jiang Liu, Shiew-Mei Huang, Jianghong Fan, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1

Jiang Liu, Reena Philip, K. Goldberg, 2020, Clinical Cancer Research.

Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology Considerations

Justin C. Earp, Jiang Liu, Shiew-Mei Huang, 2021, CPT: pharmacometrics & systems pharmacology.

Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non-Small Cell Lung Cancer.

Jiang Liu, Yaning Sun, Yaning Wang, 2019, Journal of pharmaceutical sciences.

Model‐Informed Drug Development Approaches to Assist New Drug Development in the COVID‐19 Pandemic

Justin C. Earp, Jiang Liu, Jianghong Fan, 2021, Clinical pharmacology and therapeutics.

Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective

Jiang Liu, Hao Zhu, Yaning Wang, 2019, The AAPS Journal.

Recommendations for Dose Selection for Adolescent Patients in Relevant Adult Oncology Clinical Trials

Jiang Liu, G. Reaman, Yaning Wang, 2021, Clinical pharmacology and therapeutics.

Improper Selection of a Pre-specified Primary Dose–Response Analysis Delays Regulatory Drug Approval

Jiang Liu, J. Gobburu, P. Jadhav, 2013, The AAPS Journal.

Detection and impact of hysteresis when evaluating a drug’s QTc effect using concentration-QTc analysis

Dhananjay D. Marathe, Jiang Liu, C. Garnett, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2020, The oncologist.

Assessment of Multi‐Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study

P. Sager, D. Strauss, N. Stockbridge, 2019, Clinical pharmacology and therapeutics.

Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions.

Jiang Liu, J. Murray, P. Jadhav, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Jiang Liu, K. Goldberg, R. Pazdur, 2018, Clinical Cancer Research.

Study Design Parameters Affecting Exposure Response Analysis of QT Data: Results From Simulation Studies

Jiang Liu, C. Garnett, Yaning Sun, 2018, Journal of clinical pharmacology.

Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory Perspective

Jiang Liu, Hao Zhu, Yaning Wang, 2022, The AAPS Journal.

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

Jiang Liu, R. Pazdur, Hong Zhao, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

Jiang Liu, R. Pazdur, R. Pragani, 2020, Clinical Cancer Research.

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2020, Clinical Cancer Research.

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.

Jiang Liu, Martha Donoghue, R. Pazdur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

Jiang Liu, K. Goldberg, P. Keegan, 2018, The oncologist.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Jiang Liu, P. Keegan, M. Chatterjee, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review

Jiang Liu, R. Pazdur, K. Korsah, 2021, Clinical Cancer Research.

Scientific white paper on concentration-QTc modeling

Georg Ferber, Christine Garnett, Peter L Bonate, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Model‐Informed Drug Development Approach to Expedite Approval: Case of Alectinib in First‐Line Anaplastic Lymphoma Kinase + Non‐Small Cell Lung Cancer

Jiang Liu, Hong Zhao, G. Blumenthal, 2019, Clinical pharmacology and therapeutics.

Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions

Yaning Wang, Justin C. Earp, Christoffer Tornoe, 2011, Clinical pharmacokinetics.

Correction to: Scientific white paper on concentration-QTc modeling

Georg Ferber, Christine Garnett, Peter L Bonate, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Model‐Informed Drug Development in Pediatric Dose Selection

Justin C. Earp, Jiang Liu, Xinyuan Zhang, 2021, Journal of clinical pharmacology.

Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling

Hao Zhu, Chao Liu, Yaning Wang, 2019, Journal of clinical pharmacology.

Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases

Jiang Liu, Xinyuan Zhang, Hao Zhu, 2022, Journal of clinical pharmacology.

FDA Approval Summary: Sotorasib for KRAS G12C Mutated Metastatic NSCLC.

Jiang Liu, R. Pazdur, Hong Zhao, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations

Jiang Liu, Reena Philip, K. Goldberg, 2021, Clinical Cancer Research.

Utility of Normalized TdP Score System in Drug Proarrhythmic Potential Assessment: A Blinded in vitro Study of CiPA Drugs

Jiang Liu, G. Yan, Tengxian Liu, 2020, Clinical pharmacology and therapeutics.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Manash S. Chatterjee, Jiang Liu, P. Keegan, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

Jiang Liu, Reena Philip, Martha Donoghue, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement.

Jiang Liu, L. Fashoyin-Aje, Martha Donoghue, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Approval Summary: Ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation.

Jiang Liu, L. Fashoyin-Aje, R. Pazdur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety of Serial Monthly Administration of Triple‐Dose Gadopentetate Dimeglumine in Multiple Sclerosis Patients: Preliminary Results of the BECOME Trial

Jiang Liu, N. Sethi, L. Wolansky, 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?

Jiang Liu, Jeffrey B. Kraft, K. Chan-Tack, 2014, International journal of clinical pharmacology and therapeutics.

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.

Jiang Liu, R. Pazdur, L. Amiri-Kordestani, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDA Approval Summary: Amivantamab for the Treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.

Jiang Liu, Jielin Sun, Reena Philip, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Special Section on Pediatric Drug Disposition and Pharmacokinetics Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling

Justin C. Earp, Jiang Liu, D. Tibboel, 2016 .

US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer

Jiang Liu, I. Zineh, Atiqur Rahman, 2023, CPT: pharmacometrics & systems pharmacology.